These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 21441850)
21. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Park JM; Lake KD; Arenas JD; Fontana RJ Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458 [TBL] [Abstract][Full Text] [Related]
22. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172 [TBL] [Abstract][Full Text] [Related]
24. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
25. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients. Palladino M; Laurenti L; Chiusolo P; Piccioni P; Innocenti I; Tarnani M; Sorà F; Sica S; Leone G Acta Haematol; 2010; 123(4):230-4. PubMed ID: 20424437 [TBL] [Abstract][Full Text] [Related]
26. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. Manuel O; Perrottet N; Pascual M Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513 [TBL] [Abstract][Full Text] [Related]
27. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Manuel O; Pascual M; Perrottet N; Lamoth F; Venetz JP; Decosterd LA; Buclin T; Meylan PR Clin Transplant; 2010; 24(6):794-800. PubMed ID: 20105200 [TBL] [Abstract][Full Text] [Related]
28. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Green M; Reyes J; Nour B; Beatty D; Kaufman M; Wilson J; Todo S; Tzakis A Transplant Proc; 1994 Feb; 26(1):173-4. PubMed ID: 8108926 [No Abstract] [Full Text] [Related]
29. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072 [No Abstract] [Full Text] [Related]
30. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation. Fortún Abete J; Martín-Dávila P; Moreno S; Quijano Y; de Vicente E; Pou L Antimicrob Agents Chemother; 2004 Jul; 48(7):2782-3. PubMed ID: 15215150 [No Abstract] [Full Text] [Related]
32. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. Kiser TH; Fish DN; Zamora MR J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377 [TBL] [Abstract][Full Text] [Related]
34. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540 [TBL] [Abstract][Full Text] [Related]
35. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403 [TBL] [Abstract][Full Text] [Related]
36. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy. Reischig T Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614 [TBL] [Abstract][Full Text] [Related]
37. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. Humar A; Siegal D; Moussa G; Kumar D J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456 [TBL] [Abstract][Full Text] [Related]
38. Successful treatment of cytomegalovirus disease with 9-(1,3-dihydroxy-2-propoxymethyl guanine). de Hemptinne B; Lamy ME; Salizzoni M; Cornu C; Mostin J; Fevery J; De Groote V; Otte JB Transplant Proc; 1988 Feb; 20(1 Suppl 1):652-5. PubMed ID: 2831645 [No Abstract] [Full Text] [Related]